Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus

Hepatology

Volumn 52, Issue 5, 2010, Pages 1531-1542

  Ndongo, Ndiémé ^a,b   Berthillon, Pascale ^a,b   Pradat, Pierre ^a,b,c   Vieux, Claude ^c   Bordes, Isabelle ^a,b   Berby, Françoise ^a,b   Maynard, Marianne ^c   Zoulim, Fabien ^a,b,c   TréPo, Christian ^a,b,c   Petit, Marie Anne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

E1E2A ANTIBODY; EPITOPE; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; OPTICAL DENSITY; PREDICTION AND FORECASTING; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN PURIFICATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SURFACE PROPERTY; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; EPITOPES; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; LONGITUDINAL STUDIES; PEPTIDES; REPRODUCIBILITY OF RESULTS; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 78049502705     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23862     Document Type: Article

References (19)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441.
2. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-633.
3. Boonstra A, van der Laan LJW, Vanwolleghem T, Janssen HLA. Experimental models for hepatitis C virus infection. HEPATOLOGY 2009; 50: 1646-1655.
4. Gondeau C, Pichard-Garcia L, Maurel P. Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther 2009; 124: 1-22.
5. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007; 104: 6025-6030.
6. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, et al. Human serum facilitates hepatitis C infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79: 6023-6034.
7. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 2005; 102: 4560-4565.
8. Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwai M, et al. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. J Clin Virol 2007; 39: 288-294.
9. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 18285-18295.
10. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. HEPATOLOGY 2006; 43: 592-601.
11. Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 2007; 88: 2991-3001.
12. Petit MA, Jolivet-Reynaud C, Peronnet E, Michal Y, Trépo C. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope. J Biol Chem 2003; 278: 44385-44392.
13. Petit MA, Lièvre M, Peyrol S, De Sequeira S, Berthillon P, Ruigrok RW, et al. Enveloped particles in the serum of chronic hepatitis C patients. Virology 2005; 336: 144-153.
14. Ndongo N, Rechoum R, De Sequeira S, Zoulim F, Trépo C, Drouet E, et al. Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody. J Med Virol 2009; 81: 1726-1733.
15. Ziesel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. HEPATOLOGY 2008; 48: 299-307.
16. Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C infection. PLoS One 2007; 2: e649.
17. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JP, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. HEPATOLOGY 2006; 44: 1617-1625.
18. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation of IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
19. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.